OncLive TV

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.

Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.

Juan Vasquez, MD, discusses how loss of NAPRT expression may serve as a biomarker for antitumor activity with NAMPT inhibition in rhabdomyosarcoma.

Mikkael A. Sekeres, MD, discusses the design of a study assessing the correlation between smoking intensity and genetic mutations in patients with MDS.

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.

Marwan Fakih, MD, discusses the clinical relevance of the FDA’s approval of retifanlimab for patients with squamous cell carcinoma of the anal canal.

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Brad S. Kahl, MD, explains the importance of identifying less intensive induction regimens for older patients with mantle cell lymphoma.

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

Armin Sobh, PhD, discusses the therapeutic potential of selectively targeting NSD2 in the treatment of multiple myeloma.

Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the safety of letrozole, abemaciclib, and metformin in ER-positive, recurrent endometrial cancer.

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.

Allison Winter, MD, emphasizes the importance of carefully evaluating treatment history in patients with Richter transformation from CLL.

Anthony M. Hunter, MD, discusses the role of momelotinib for the treatment of adult patients with myelofibrosis and moderate to severe anemia.

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.